Together these observations demonstrate that the VDRFF variant is an effective negative modulator of 1,25D3 on estrogen receptor mediated signaling and that breast cancer patients whose cells express the FF genotype may benefit from vitamin D therapy. This evidence concerns the gene ESR1 and breast cancer.